ReviewFrontiers in immunology2026
Fueling bone loss: the immunometabolic reprogramming of the bone microenvironment in diabetic osteoporosis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic osteoporosis (DOP) is a serious skeletal complication of type 2 diabetes mellitus (T2DM), characterized by deteriorated bone microarchitecture and elevated fracture risk independent of reduced bone mineral density. Emerging evidence indicates that immunometabolic reprogramming of bone marrow immune cells serves as a core driver of DOP pathogenesis. This review focuses on macrophages and CD4+ Th17/Treg cells, the pivotal immune subsets mediating skeletal immune-metabolic homeostasis. We systematically elaborate how hyperglycemia triggers glycolytic predominance, HIF-1α stabilization, and succinate-SUCNR1 axis activation in macrophages, alongside mTORC1-HIF-1α-dependent Th17/Treg imbalance. Bidirectional immunometabolic crosstalk between these immune cells disrupts the RANKL/OPG and Wnt/β-catenin signaling pathways, thereby disturbing bone formation and resorption. Furthermore, we summarize current immunometabolic-targeted modulators for DOP, stratifying their preclinical and clinical evidence, skeletal benefits, and safety limitations. We also highlight existing clinical diagnostic defects and translational bottlenecks in DOP research. Finally, we prospect emerging research directions including spatial immunometabolic profiling, gut-immune-bone axis regulation, and artificial intelligence-assisted precision intervention, aiming to provide mechanistic insights and novel translational strategies for DOP targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.